Beam Therapeutics Inc.
BEAM
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$17.82
Price+1.08%
$0.19
1Y
Price
Market Cap
$1.803b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-1332.0%
EBITDA Margin-1331.6%
Net Profit Margin-1379.0%
Free Cash Flow MarginRevenue
$60.272m
-4.4%
1y CAGR+177.7%
3y CAGR+54112.4%
5y CAGREarnings
-$398.583m
-1.7%
1y CAGR+23.6%
3y CAGR+9.4%
5y CAGREPS
-$4.50
-3.5%
1y CAGR+26.6%
3y CAGR+20.8%
5y CAGRBook Value
$1.047b
$1.391b
Assets$344.344m
Liabilities$154.803m
DebtDebt to Assets
11.1%
-0.9x
Debt to EBITDAFree Cash Flow
-$355.572m
+7.5%
1y CAGR-169.4%
3y CAGR-127.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company